Abstract
Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Current Gene Therapy
Title:Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer
Volume: 13 Issue: 1
Author(s): Qing Zhang, Huizhong Li, Jie Yang, Liantao Li, Baofu Zhang, Jia Li and Junnian Zheng
Affiliation:
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Abstract: Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Export Options
About this article
Cite this article as:
Zhang Qing, Li Huizhong, Yang Jie, Li Liantao, Zhang Baofu, Li Jia and Zheng Junnian, Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer, Current Gene Therapy 2013; 13 (1) . https://dx.doi.org/10.2174/1566523211313010007
DOI https://dx.doi.org/10.2174/1566523211313010007 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Rho GTPases by Peptidic Structures
Current Pharmaceutical Design Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Current Pharmaceutical Design Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis
Current Pharmaceutical Biotechnology Targeting Cellular Proapoptotic Molecules for Developing Anticancer Agents from Marine Sources
Current Drug Targets Learning from Multiple Classifier Systems: Perspectives for Improving Decision Making of QSAR Models in Medicinal Chemistry
Current Topics in Medicinal Chemistry Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Isolation and Characterization of a Trypsin-Chymotrypsin Inhibitor from the Seeds of Green Lentil (Lens culinaris)
Protein & Peptide Letters Editorial: [Hot Topic: Molecular Pathology in Therapeutics: Where are We Now, and Where are We Going?]
Current Drug Targets Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Metastatic Brain Tumors: To Treat or Not to Treat, and with What?
Current Cancer Therapy Reviews 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Therapeutic Cancer Vaccines
Current Cancer Therapy Reviews Quantification of Glycyrrhetic Acid in Human Plasma by LC–MS/MS: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry